The drugmaker attributes the forecasted revenue and adjusted earnings to a strong demand for its recently launched diabetes and psoriasis drugs. In addition, the company expects additional progress in its drug portfolio in 2018, including a new rheumatoid arthritis treatment.
Even though Eli Lilly has seen increased competition from biosimilars entering the market, the company reaffirmed its expectation of at least a 5 percent annual revenue growth rate from 2015 to 2020.
More articles on supply chain:
10 recent pharma layoffs
Sanofi urges Philippine government to lift suspension of its dengue vaccine
Medline to relocate supply distribution center in Maryland, triple its workforce
